{
    "name": "mitapivat",
    "comment": "Rx",
    "other_names": [
        "Pyrukynd"
    ],
    "classes": [
        "Pyruvate Kinase-R Activators"
    ],
    "source": "https://reference.medscape.com/drug/pyrukynd-mitapivat-4000241",
    "pregnancy": {
        "common": [
            "Available data are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes"
        ],
        "specific": [
            {
                "type": "Clinical considerations",
                "description": [
                    "PK deficiency in pregnant women may precipitate acute hemolysis, preterm labor, miscarriage, and severe anemia requiring frequent transfusion",
                    "Preeclampsia and severe hypertension also reported"
                ]
            },
            {
                "type": "Animal data",
                "description": [
                    "Oral administration to pregnant rats and rabbits during organogenesis was not teratogenic at doses up to 13x and 3x the maximum recommended human dose (MRHD) of 50 mg twice daily, respectively",
                    "Oral administration to pregnant rats twice daily during organogenesis through lactation did not result in adverse developmental effects at doses up to 13x MRHD"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of mitapivat or its metabolites in human or animal milk, effects on breastfed children, or effects on milk production",
            "Consider developmental and health benefits of breastfeeding along with the motherâ€™s clinical need and any potential adverse effects on the breastfed child or from the underlying maternal condition "
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Acute hemolysis with abrupt treatment interruption",
                    "description": [
                        "Acute hemolysis with subsequent anemia observed following abrupt interruption or discontinuation",
                        "Avoid abruptly discontinuation",
                        "Gradually taper dose to discontinue treatment if possible",
                        "When discontinuing treatment, monitor for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "Substrate of CYP3A4",
                        "Induces CYP3A4, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 enzymes",
                        "Also, induces UGT1A1",
                        "Substrate and inhibitor of P-glycoprotein (P-gp)",
                        "Strong or moderate CYP3A4 inhibitors",
                        "Strong CYP3A4 inhibitors: Avoid coadministration",
                        "Moderate CYP3A4 inhibitors: Monitor Hb and for increased risks of adverse reactions with mitapivat; do not titrate mitapivat beyond 20 mg BID",
                        "Strong or moderate CYP3A inhibitors increase plasma concentrations and risks of adverse reactions of mitapivat",
                        "Strong or moderate CYP3A4 inducers",
                        "Strong CYP3A4 inducers: Avoid coadministration",
                        "Moderate CYP3A4 inducers: Consider other drugs that are not moderate CYP3A inducers when coadministered with mitapivat; if coadministration unavoidable, monitor Hb and titrate beyond 50 mg BID, if necessary (not to exceed 100 mg BID)",
                        "Strong or moderate CYP3A inducers decrease plasma concentrations and efficacy of mitapivat",
                        "Sensitive CYP3A4, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 substrates",
                        "Monitor for loss of therapeutic effect of sensitive CYP3A4, CYP2B6, CYP2C8, CYP2C9, and CYP2C19 substrates with narrow therapeutic index when coadministered with mitapivat",
                        "Mitapivat may decrease systemic concentrations of sensitive CYP3A4 (eg, hormonal contraceptives), CYP2B6, CYP2C8, CYP2C9, and CYP2C19 substrates",
                        "Advise patients using hormonal contraceptives to use a nonhormonal contraceptive method or add a barrier method of contraception during treatment",
                        "UGT1A1 substrates",
                        "Monitor for loss of therapeutic effect of UGT1A1 substrates with narrow therapeutic index when coadministered with mitapivat",
                        "Mitapivat may decrease systemic concentrations of UGT1A1 substrates with narrow therapeutic index",
                        "P-gp substrates",
                        "Monitor for adverse reactions of P-gp substrates with narrow therapeutic index when coadministered with mitapivat",
                        "Mitapivat may increase systemic concentrations of drugs that are P-gp substrates"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mavacamten",
            "description": {
                "common": "mitapivat will decrease the level or effect of mavacamten by  affecting hepatic enzyme CYP2C19 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pacritinib",
            "description": {
                "common": "mitapivat will decrease the level or effect of pacritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elacestrant",
            "description": {
                "common": "mitapivat will decrease the level or effect of elacestrant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "mitapivat will decrease the level or effect of ganaxolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ganaxolone with moderate or strong CYP3A4 inducers. If coadministration unavoidable, consider increasing ganaxolone dose; however, do not exceed maximum daily dose for weight."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "mitapivat will increase the level or effect of lenacapavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of lenacapavir with moderate CYP3A4 inducers."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "mitapivat will decrease the level or effect of leniolisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumateperone",
            "description": {
                "common": "mitapivat will decrease the level or effect of lumateperone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olutasidenib",
            "description": {
                "common": "mitapivat will decrease the level or effect of olutasidenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong or moderate CYP3A inducers decrease olutasidenib (a CYP3A4 substrate) plasma concentrations and efficacy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "mitapivat will decrease the level or effect of omaveloxolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vonoprazan",
            "description": {
                "common": "mitapivat will decrease the level or effect of vonoprazan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "mitapivat will decrease the level or effect of zanubrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of zanubrutinib (a CYP3A4 substrate) with moderate CYP3A4 inhibitors. If unavoidable, increase zanubrutinib dose to 320 mg PO BID. After discontinuing the CYP3A4 inhibitor, resume previous dose of zanubrutinib. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of mitapivat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lencapavir (a moderate CYP3A4 inhibitor) increases mitapivat (CYP3A4 substrate) levels and risk of adverse reactions. When coadministered, dose of mitapivat should not exceed 20 mg BID."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "mitapivat will decrease the level or effect of warfarin by  affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Arthralgia",
            "percent": "10"
        },
        {
            "name": "Hypertriglyceridemia",
            "percent": "8"
        },
        {
            "name": "Gastroenteritis",
            "percent": "8"
        },
        {
            "name": "Hot flush",
            "percent": "8"
        },
        {
            "name": "Oropharyngeal pain",
            "percent": "8"
        },
        {
            "name": "Hypertension",
            "percent": "5"
        },
        {
            "name": "Arrhythmia",
            "percent": "5"
        },
        {
            "name": "Breast discomfort",
            "percent": "5"
        },
        {
            "name": "Constipation",
            "percent": "5"
        },
        {
            "name": "Dry mouth",
            "percent": "5"
        },
        {
            "name": "Paresthesia",
            "percent": "5"
        },
        {
            "name": "Hypertriglyceridemia",
            "percent": "5"
        },
        {
            "name": "Hypertension",
            "percent": "5"
        },
        {
            "name": "Gastroenteritis",
            "percent": "3"
        }
    ]
}